Key result
Lisinopril increases serious cardiovascular events ~136% vs atenolol in hemodialysis patients, prompting early trial termination.
Why the study?
Does lisinopril improve left ventricular mass index compared to atenolol in maintenance hemodialysis patients with hypertension and left ventricular hypertrophy?
Population
200 maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension
Comparison
Open-label lisinopril administered three times… vs Open-label atenolol administered three times per…
Design
RCT, randomly assigned, open-label
Follow-up
12 months
Authors
Loading...
Atenolol should be prioritized over lisinopril for hypertension in hemodialysis; challenges ACEI preference and warrants confirmation in larger trials.
RCT (n=200)
open-label
randomly assigned
Does lisinopril improve left ventricular mass index compared to atenolol in maintenance hemodialysis patients with hypertension and left ventricular hypertrophy?
In hemodialysis patients with hypertension and LVH, atenolol-based therapy was superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations, despite similar effects on LV mass regression.
Agarwal et al. (2014) conducted an RCT in Hypertension and left ventricular hypertrophy in maintenance hemodialysis patients (n=200). lisinopril vs. atenolol was evaluated on change in left ventricular mass index (LVMI) from baseline to 12 months. Lisinopril therapy increased the risk of serious cardiovascular events compared to atenolol (IRR 2.36; 95% CI 1.36-4.23; P=0.001) in hemodialysis patients, prompting early trial termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: